Open AccessCanakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design
Author(s) -
Pilar Garrido,
Jean-Louis Pujol,
Edward S. Kim,
Jay M. Lee,
Masahiro Tsuboi,
Ana Gómez-Rueda,
Amparo Benito,
Nicolás Moreno,
Luis Gorospe,
Tuochuan Dong,
Cecile Blin,
Vanessa Rodrik-Outmezguine,
Vanessa Q. Passos,
Tony Mok
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1098
Subject(s) - canakinumab , medicine , pembrolizumab , lung cancer , cancer , oncology , immunotherapy , disease , anakinra
Canakinumab is a human IgGκ monoclonal antibody, with high affinity and specificity for IL-1β. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial, evaluating canakinumab for cardiovascular disease, provided the first signal of the potential of IL-1β inhibition on lung cancer incidence reduction. Here, we describe the rationale and design for CANOPY-N, a randomized Phase II trial evaluating IL-1β inhibition with or without immune checkpoint inhibition as neoadjuvant treatment in patients with non-small-cell lung cancer. Patients with stage IB to IIIA non-small-cell lung cancer eligible for complete resection will receive canakinumab or pembrolizumab as monotherapy, or in combination. The primary end point is major pathological response by central review; secondary end points include overall response rate, major pathological response (local review), surgical feasibility rate and pharmacokinetics. Clinical trial registration: NCT03968419 (ClinicalTrials.gov)